Industry & Policy News

[BioMarin Pharmaceutical, Inc.] BioMarin Pharmaceutical Inc. announced that the US FDA approved ROCTAVIAN™ gene therapy for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.

[McMaster University] McMaster University has received $6.8M from the federal government as part of a national initiative to create a Canadian Medical Isotope Ecosystem – a pan-Canadian network for medical isotope research and innovation.

[Microsoft] The National Health Service at Addenbrooke’s Hospital in Cambridge is now able to plan radiotherapy treatments faster than in the past, thanks to AI advances that are cutting wait times. Working alongside this AI technology, specialists can plan radiotherapy treatments approximately two and half times faster than if they were working alone, ensuring more patients can get treatment sooner and improving the likelihood of better outcomes.

[University of California] Andrew Goldstein, associate professor of molecular, cell and developmental biology and urology at the David Geffen School of Medicine at UCLA, received a $900,000 Idea Development Award from the Department of Defense to study how metabolism changes in prostate cancer as a result of hormone therapy, the most commonly used treatment for men with advanced disease.

[UCB] RYSTIGGO® injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.1,4. It is the only FDA-approved treatment in adults for both anti-acetylcholine receptor andanti-muscle-specific tyrosine kinase antibody-positive generalized myasthenia gravis.

[Biora Therapeutics, Inc.] Biora Therapeutics, Inc. announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development. The patents are directed to methods of treating ulcerative colitis using an ingestible device that delivers one or more therapeutic agents to the proximal part of the large intestine.